ETBONDAIETBONDAI
Non-Confidential Teaser

Patent Allowed — Upstream Complement for Blindness.

Safe to share without an NDA. Designed to start the conversation — then mutual NDA unlocks the confidential deck, data room, and management call.

ETBONDAI, Inc. — Confidential Teaser for Licensing

Patent Allowed: Prophylaxis and Therapy of Ocular Diseases Leading to Blindness

Contact: Kumar Shah, MD · 326 Livingston Street, Brooklyn, NY 11217 · (347) 302-3107 · etbondai.com

The Problem

Downstream is not enough

Geographic Atrophy (GA) affects ∼1.5M patients in the US alone. First approved complement drugs — Syfovre (C3 inhibitor) and Izervay (C5 inhibitor) — slow lesion growth only 16–22% and require chronic intravitreal injections with vasculitis risk.

Why? They act downstream. The cascade has already fired.

The Solution

Upstream control

ETBONDAI owns Patent Allowed for upstream inhibition via Complement Factor H modulation.

Factor H is the master regulator of complement — 150 kDa, 20 SCR domains, a molecular rosary. When Factor H fails, complement over-activates, RPE is damaged, photoreceptors die.

ETBONDAI controls the cascade at its source — upstream control.

The Translation

Phase 0 detective gate

ETBONDAI has developed a Single-Patient IND-ready protocol with a unique decision gate — designed to move from patent-allowed science into a disciplined clinical next step.

The Opportunity

  • Patent Status: Patent Allowed, US + PCT pending
  • Field Available: Ophthalmic use — exclusive license available; retained by ETBONDAI
  • Market: GA market $5.8B in 2024, projected $7.6B by 2031. Complement inhibitor market growing 22.7% CAGR
  • Synergy: Licensee with downstream C3/C5 asset gains upstream control and owns the full cascade
  • Next Step: Single Patient IND (FDA Form 3926) ready for filing

What We Seek

Exclusive option / license — ophthalmic field

Partner with complement and retina development capability. Structure: option fee + license fee + development milestones + royalties on net sales.

Next step: Mutual NDA → Confidential Deck + Data Room + Management Call with Dr. Shah.

Request NDA conversation Email Dr. Shah

Suggested BD subject line: Patent Allowed — Upstream Complement (Factor H) for GA — Exclusive Ophthalmic License